36
Healthcare Sector Analysis Alexander Bishop Justin Gibbs Bethaditya Winarno Jie Zhang

Healthcare Sector Analysis

Embed Size (px)

DESCRIPTION

Healthcare Sector Analysis. Alexander Bishop Justin Gibbs Bethaditya Winarno Jie Zhang. Agenda. Healthcare Sector Overview Business Analysis Economic Analysis Financial Analysis Valuation Analysis Recommendations Q&A. Healthcare overview. - PowerPoint PPT Presentation

Citation preview

Page 1: Healthcare Sector Analysis

Healthcare Sector Analysis

Alexander BishopJustin Gibbs

Bethaditya WinarnoJie Zhang

Page 2: Healthcare Sector Analysis

Agenda Healthcare Sector Overview

Business Analysis

Economic Analysis

Financial Analysis

Valuation Analysis

Recommendations

Q&A

Page 3: Healthcare Sector Analysis

Healthcare overview

Page 4: Healthcare Sector Analysis

A category of stocks relating to medical and healthcare goods or services, the sector market capitalization is at $1.96 Trillion

Page 5: Healthcare Sector Analysis

Healthcare Industries

Page 6: Healthcare Sector Analysis

Company Name Industry Market Cap. ($ MIL)

JOHNSON & JOHNSON Pharmaceutical 174000.000

PFIZER Pharmaceutical 144000.000

MERCK & CO. Pharmaceutical 113000.000

ABBOTT LABORATORIES Pharmaceutical 83000.000

AMGEN Biotechnology 57000.000

MEDTRONIC HC-Equipment 47000.000

GILEAD SCIENCES Biotechnology 42000.000

BRISTOL-MYERS SQUIBB Pharmaceutical 41000.000

LILLY (ELI) Pharmaceutical 39000.000

UNITEDHEALTH GROUP HC-Managed Care 38000.000

Sector Leading Companies

Page 7: Healthcare Sector Analysis

SIM Holdings

Security Ticker %age Assets Eq shares outAmgen Inc. AMGN 2.65% 995.000

CareFusion Corp. CFN 0.88% 221.384

Gilead Sciences Inc. GILD 3.35% 899.925 Johnson & Johnson Co. JNJ 3.76% 2,759.100

Teva Pharmaceutical Industries Ltd. TEVA 3.64% 923.960

Page 8: Healthcare Sector Analysis
Page 9: Healthcare Sector Analysis
Page 10: Healthcare Sector Analysis
Page 11: Healthcare Sector Analysis

Sector Performance

YTD: -1.65% QTD: -1.65%

Top 5 Performers

Berkshire Hathaway Inc. 15.52%

Gilead Sciences Inc. 11.56%

NCR Corp. 7.55%

TCF Financial Corp. 7.49%

Amgen Inc.   3.38%

Page 12: Healthcare Sector Analysis

Business Analysis

Page 13: Healthcare Sector Analysis

Phase of Life Cycle

Page 14: Healthcare Sector Analysis

Aging of US population, 16% of US population will be 65+ older by 2020.

Key Driver: Demographic

Page 15: Healthcare Sector Analysis

Porter Five Forces Analysis

• Rivalry: Highly concentrated in large companies, competition between largest companies

• Supplier Power: Low• Substitutes: Generic drugs• Buyer Power: Low, buyers are individual

consumers• Barriers to enter: long & costly FDA approval (10

years on average), high R&D cost, R&D process is very difficult and tedious

Page 16: Healthcare Sector Analysis

Patent Expiration

• Patents grant exclusive rights for 20 years• Generic drug is a low cost substitute• Increasing use of generic drugs

Page 17: Healthcare Sector Analysis

• Substantial loss in market share

Page 18: Healthcare Sector Analysis

Economic Analysis

Page 19: Healthcare Sector Analysis

Positive trends

• Aging population and the baby boomers• People living longer with chronic disease • Obesity and diabetes epidemics • Technological advances • Global reach of disease • Personalized medicine

Page 20: Healthcare Sector Analysis

US Projected Population from 2010-2050

Page 21: Healthcare Sector Analysis

US Obesity Trend

No Data <10% 10%–14% 15%–19% 20%–24% 25%–29% ≥30%

Page 22: Healthcare Sector Analysis

Trends in National Health Expenditure

Page 23: Healthcare Sector Analysis

Healthcare Reform

• Could be beneficial to the industry because more people will be insured and able to seek out medical attention.

• With more people insured, the number of medical procedures performed should increase.

• The sector has been oversold out

Page 24: Healthcare Sector Analysis

Financial Analysis

Page 25: Healthcare Sector Analysis

EBITDA MARGIN

E B IT DA MAR G IN

0.0%

10.0%

20.0%

30.0%

40.0%

50.0%

60.0%

2005 2006 2007 2008 2009

Healthc are

B iotec h

Dis tributors

P harma

E quipment

S + P 500

Page 26: Healthcare Sector Analysis

NET PROFIT MARGINNet P rofit Marg in

0.0%

5.0%

10.0%

15.0%

20.0%

25.0%

30.0%

35.0%

2005 2006 2007 2008 2009

Healthc are

B iotec h

Dis tributors

P harma

E quipment

S + P 500

Page 27: Healthcare Sector Analysis

RETURN ON EQUITYR eturn on E quity

0.0%

5.0%

10.0%

15.0%

20.0%

25.0%

30.0%

35.0%

2005 2006 2007 2008 2009

Healthc are

B iotec h

Dis tributors

E quipment

S + P 500

Page 28: Healthcare Sector Analysis

REVENUE GROWTH

R evenue Growth

0

2

4

6

8

10

12

14

2004-2005 2005-2006 2006-2007 2007-2008

Healthc are

S + P 500

Page 29: Healthcare Sector Analysis

EARNINGS PER SHARE

E P S

0

20

40

60

80

100

2005 2006 2007 2008 2009

Healthc are

S + P 500

Page 30: Healthcare Sector Analysis

CASH FLOW/ SHARE

C as h F low/ S hare- Healthc are

20

25

30

35

40

2005 2006 2007 2008 2009

C as h F low/ S hare- S +P

8090

100110120130140150160

2005 2006 2007 2008 2009

Page 31: Healthcare Sector Analysis

Valuation Analysis

Page 32: Healthcare Sector Analysis

Current Valuations

•Below the median in every category•Valuations will revert to the mean after restored market confidence•Not due to a change in industry fundamentals•Future drivers of Revenue look promising

•Demographics•Penetration in emerging markets•Healthcare expenditures up

Page 33: Healthcare Sector Analysis

Relative to S&P 500

Page 34: Healthcare Sector Analysis

Recommendations

Page 35: Healthcare Sector Analysis

Recommendations Add 38 basis points to increase current weight to150 basis points overweight

Reasons:1.Constant revenue growth, outperforming S&P5002.Short-term modest economic growth3.Healthcare reform4.Patent expiration

Page 36: Healthcare Sector Analysis

Questions?